

SERVICE CHARTER



ISTITUTO DI CANDIOLO
Fondazione del Piemonte
per l'Oncologia

**ISTITUTO DI RICOVERO E
CURA A CARATTERE
SCIENTIFICO**

www.fpoircc.it



QUALITY TEAM

WHY TURN TO CANDIOLO IRCCS?

...BECAUSE OF THE EXPERIENCE AND COMPETENCE THAT IT OFFERS

its clinical and research professionals can boast rare experience and competence in oncology as attested by the over 1,000 articles published in international scientific journals over the last 7 years and by a total of 11,000 citations from other researchers nationally and internationally, who have deemed our research projects worthy of consideration and to be of high scientific impact.

...BECAUSE OF ITS SYNERGY BETWEEN RESEARCH AND CARE

the IRCCS is also a Research Centre of international standing in the field of oncology; Research and Clinical Practice are at one, and make possible the immediate transferral of the scientific breakthroughs to the patient's bed, ensuring the most up-to-date and personalized therapeutic approaches.

...BECAUSE OF THE SWIFTNES WITH WHICH THE PATIENT IS TAKEN INTO CARE

each patient is immediately taken into care by our specialists, who plan the entire diagnostic and therapeutic path and spare the patient any inconvenience with regard to booking appointments and administrative formalities; waiting times for our patients are minimal.

...BECAUSE OF THE SAFETY OF THE CARE

the Institute is equipped with a 24/7 intensive care unit and offers consultations for all specialist branches.

...BECAUSE OF ITS CUTTING-EDGE TECHNOLOGY

our surgical operations benefit from the use of minimally invasive or robotic techniques that make it possible to combine the radical result of the operation with a reduction in post-operative complications, limiting to a minimum aesthetic and functional discomfort. Medical Imaging, Nuclear Medicine and Radiation Therapy are here at the cutting edge in terms of the modernity of the equipment and the skill of the specialists in the fields of medical imaging and radiation therapy.

...BECAUSE OF THE COMFORTABLE ENVIRONMENT

common areas and rooms and wards have been designed and created following the most up-to-date canons of hotel architecture, highlighting the size and quality of the rooms (lighting, colour schemes, furnishings); each room is equipped with a television, telephone and private bathroom; the parking areas can accommodate 800 vehicles around the clock and free of charge.

...BECAUSE OF THE HUMANITY OF THE CARE AND THE SOLIDARITY DISPLAYED

throughout the daytime a relative/helper may stay in the patient's room; the Institute has special arrangements with residential facilities which, free of charge, accommodate "away from home" patients and, where necessary, a helper for the duration of the period of care; equally, both patients and helpers are provided with free meals in the Institute's restaurant.



THE MISSION

RESPECT FOR THE PRINCIPLES OF THE CENTRALITY OF THE INDIVIDUAL IS AT THE HEART OF ALL CLINICAL AND RESEARCH ACTIVITIES UNDERTAKEN AT THE INSTITUTE.

The IRCCS intends to contribute to the fight against cancer through the synergy between scientific research and strategies of diagnosis and care, in collaboration, too, with the University of Turin and the most prestigious national and international scientific institutions. A quite specific objective of the Institute is represented by the study of the technical and organizational dynamics necessary for a rapid transferral of the preclinical experimental data to clinical practice. Another important goal, pursued by researchers and clinicians, is the cultural and experiential enrichment of the scientific community: scientists and doctors at the Institute boast numerous publications and citations in the most important international scientific journals.



THE HOSPITALITY OF CANDIOLO IRCCS

For any patients and their helpers coming from localities far from the Institute, who might encounter difficulties in finding accommodation during the course of their of diagnosis and care, the Institute makes available, free of charge, partner residential facilities. Patients and their helpers are also provided with free meals in the Institute's restaurant.

CLINICAL ACTIVITIES

Opened in 1997, the Candiolo Institute is an oncological centre dedicated to clinical-healthcare activities and to scientific research. In 2013 it was granted the status of IRCCS (Institute for Admission and Care for Purposes of Scientific Advancement). It performs its activities both in arrangement with the Italian National Health Service and with private patients.

In 2016 it obtained ISO quality certification 9001:2015 for all its areas of activity: diagnosis, treatment, assistance, research, administration, training, ethical committee.

The care pathway of the patient undergoing a haematopoietic bone marrow transplant has obtained the prestigious international JACIE-FACT accreditation. In addition, the Institute can boast HIMSS (Healthcare Information Management Systems Society) certification reflecting high technological standards and security with in questions of digitization of clinical and administrative documentation.

The Candiolo Institute has become, on the basis of a specific resolution of the Piedmont Regional Government dated 23.11.2015, a centre of reference for onco-haematological tumours, breast cancers, gynaecological tumours, colorectal tumours, tumours of the stomach, otorhinolaryngological tumours, urological tumours, skin cancers, sarcomas, tumours of the liver and of the intrahepatic bile ducts and tumours of the pancreas and of the extrahepatic bile ducts. In the course of 2015 Candiolo IRCCS also earned the role of regional single-specialty centre of reference for the management of oncological pain (DGR 29.12.2015).



The IRCCS is authorized and accredited by the regional healthcare authority for the management of **150 beds: 70 in the medical area, 70 in surgery, and 10 in intensive care.**

In medical oncology, in addition to traditional chemotherapy, molecularly targeted therapies and immunotherapeutic treatments are also performed.

Candiolo IRCCS is one of the most important oncological facilities in Italy in terms of the number of patients treated for breast cancer (5,000 patients are currently in treatment or in follow-up) and for sarcomas (600 individuals in treatment or follow-up).

At the Institute surgical treatment of tumours makes use, above all in cervicocephalic, hepatobiliary-pancreatic-colorectal and gynaecological surgery, of minimally invasive techniques which allow excellent results while preserving aesthetic and functional integrity to the maximum. The Institute can be proud of its consolidated experience in the surgery of primitive and secondary peritoneal tumours.

Furthermore, recent times have seen the introduction of the surgical treatment of pulmonary and mediastinal primitive and metastatic neoplasms, as well as the performance of diagnostic-interventional procedures (trans-bronchial, lymph node, and pulmonary biopsies, bronchial deobstructions, endoprosthesis positioning, mediastinoscopies).

Another new specialist area has recently been entered with the beginning of urological surgery activities comprising the treatment of the complex surgical pathologies: locally-advanced prostate cancer and/or cancer already subjected to primary radiation therapy, and even hormone therapy, bladder cancer refractory to catheter-based therapies, widespread renal neoplasms, residual masses in germinal neoplasms.





ISTITUTO DI
RICOVERO E
CURA A CARATTERE
SCIENTIFICO



In the field of imaging, scans are performed (CAT, NMR, ultrasound) for prevention, diagnostic and staging purposes and for the monitoring of tumoral diseases. Our radiologists are recognised for their experience of many years in the execution of virtual colonoscopies (for an early diagnosis of tumours of the colon) and multiparameter NMR of the prostate (which bring to light tumours of the prostate in the early stage, providing, at the same time, information on the morphology, cellularity and vascularization of neoformations). Interventional radiology treatments are carried out - in particular, vertebroplasties, embolizations, drainage of the bile ducts and urinary tract, percutaneous biopsies.

Our gastroenterology service, in addition to the standard esami diagnostic endoscopic procedures, is characterized by its interventional activities (surgical removal of polyps, dilatation of reduced segments, treatment of bleeding lesions, endoprosthesis positioning).

Our radiation therapy team treat all neoplasms in adults, using two pieces of apparatus for tomotherapy and a TrueBeam accelerator, which combine maximum precision in the administration of the radiation beam at high speed, thus allowing for extremely targeted therapies with a high turnover of patients.

Our nuclear medicine service performs activities of diagnosis, staging and follow-up of tumoral diseases with the aid of whole body PET/CT, using fluorodeoxyglucose (18-Fdg) tracers for tumoral diseases in general, and fluoromethylcholine specifically for prostate tumours, for which it represents a fundamental aid for the early diagnosis of relapsed or residual disease.

The Institute's laboratories (Laboratory Analysis and Anatomical Pathology) are at the cutting edge in the diagnostic field of blood and solid tissues, also in terms of the molecular characterization of neoplasms.

MININVASIVE SURGERY

The "ideal" oncological surgery of the third Millennium must synergistically pursue the goals of eradication of the disease and of aesthetic-functional preservation. Advanced technologies and operator experience are crucial for any "minimally invasive" approach, for some time now the "gold standard" in the surgical treatment of various neoplastic diseases.

The minimally invasive surgical approach is in keeping with the evolution of cancer therapy linked to ever more effective and sophisticated diagnostic and therapeutic technologies, as well as to the knowledge of the molecular mechanisms underlying carcinogenesis, which make it possible to accurately define the "target", thus saving the integrity of healthy tissues and with simultaneous reduction of side effects. Over the course of the years, indeed, the therapeutic paradigm of "maximum tolerable intervention" has evolved into "minimum equally effective intervention". This evolution is tangible at the Candiolo Institute, above all in the areas of Cervicocephalic Surgery, of Surgery of the Hepatobiliary-Pancreatic and Colo-Rectal Tumours and of the Surgery of the Female Pelvis.

Moreover, the introduction of the sophisticated Da Vinci Xi robotic surgery platform (the most modern of those currently in use) allows the surgical services of the IRCCS to implement the minimally invasive approach in line with the canons of maximum precision and safety.



SCIENTIFIC RESEARCH

The **IRCCS** is characterized by its extensive clinical and translational research service, which has at its disposal over 10,000 square metres of laboratories and cutting edge instrumentation, available to over 200 researchers from Italy and abroad.

Our scientific research activities develop through the typical stages: basic research, clinical research and translational research. The latter – whose

objective it is to permit immediate transferral of results obtained from basic research to the patient's bed – has recently assumed particular significance due to the bidirectionality of implications: indeed, a correct and reasoned use of the clinical result makes possible a retrospective assessment of the preclinical model and allows for its critical revision and continuous honing.

THE BASIC TENETS OF THE INSTITUTE'S RESEARCH ACTIVITIES ARE:

TEAMWORK

The Institute has established Interdisciplinary Groups of Translational Research (Italian acronym:GIRT), thanks to whom a number of ambitious milestones have been reached (for example, the definition of a new molecular nosography for certain solid tumours, which, today, is applied internationally).

NETWORKING

The IRCCS is a member of various networks of centres of research and cancer care (regional, national and international) with which it operates synergistically in the development of new diagnostic instruments and in the planning of clinical trials which can provide patients with effective therapeutic alternatives.

RESPECT FOR ETHICAL PRINCIPLES

The members of the Ethical Committee meet each month to discuss and assess whether the individual projects and protocols related to the research and to patient care are based on principles of appropriateness, veracity, detailed information, transparency and respect for privacy.

INNOVATION

Our research structures can avail themselves of the most up-to-date and sophisticated technologies, in particular in the field of molecular biology.

THE BRANCHES OF RESEARCH OF CANDIOLO IRCCS

Candiolo IRCCS conducts “translational research”, which through its experimental approach responds to unresolved clinical queries, and “clinical research” which sees the application of translational research results directly on patients through enrolment in clinical trials.

It is clear to us now that many oncological diseases should be considered chronic and requiring attention through the years and that patients will be able to benefit from potential innovative, “targeted” therapeutic approaches even during the evolution of the disease. By “targeted therapy” we mean the use of drugs which, in a specific way, block the cause of the disease, inhibiting its growth action on cancer cells. In the ambit of the “FUTURO project” (FUTURO: Italian acronym for ‘confronting a recidive tumour from its very origin’) we intend to develop the following research strands.



● BREAST CANCERS

Translational Research → We search for new markers which on tumoral tissues permit a better diagnostic classification. We employ state-of-the-art experimental methods using immortalized tumour cells which make it possible to perform various types of tests, including analysis of the molecules implicated in the growth of the breast cancer, in particular HER2.

Clinical Research → Patients with tumours which express the receptor for the oestrogen hormone are included in a clinical trial with the possibility of treatment in the interval between pre-operative biopsy and surgery with drugs which block the receptor. In this way, it is possible to test the response to treatment assessed through the capacity to block tumoral proliferation.

We offer the possibility to assess the molecular subtype of the tumour by means of advanced technologies.

● COLORECTAL, GASTRIC AND BILIARY TUMOURS

Translational Research → On experimental models we study the molecular structure of metastatic tumours of the gastrointestinal tract, those drugs with the best results in inhibiting of tumour growth and the causes of resistance to “molecularly targeted” drugs.

Clinical Research → In a clinical trial we evaluate through the analysis, based on a “liquid biopsy”, of tumour DNA, released into the patient’s blood, the possibility of monitoring the response to molecularly targeted drugs, by modulating and modifying the therapeutic protocol in order to overcome any pharmacological resistences.

● TUMOURS OF THE HEAD AND NECK

Translational Research → The study of the tumoral environment and of the response of its own immune cells to tumours caused by HPV infections is undergoing investigation with advanced molecular methods, the aim of which is to define the mechanisms growth blocking of such neoplasms.

Clinical Research → The minisurgery approach, along with robotic surgery, is based on research and development studies also in the area of medical imaging and anatomical pathology in order to ensure the efficacy of new protocols.

● MELANOMAS

Translational Research → We have created

experimental models in vivo and in vitro which make possible assessment of the effect of combinations of molecular drugs on growth inhibition of the melanoma.

Clinical Research → For tumoral tissues there are proposed new molecular tests which assess the structure of the immune cells in order to better understand the response to innovative immunotherapeutic drugs.

● OVARIAN CANCERS

Translational Research → Comparative genetic analyses among various types of cells and tumours of the ovaries make it possible to analyze the biology of these highly-aggressive tumours and to study new chemotherapeutic combinations.

Clinical Research → There is, in the Institute, a clinical trial underway which allows us to offer new combinations of innovative drugs to patients who have not responded to traditional therapies.

● CANCER OF UNKNOWN PRIMARY

These are tumours who from their onset present with metastasis, without offering the possibility to identify the organ of origin.

Translational Research → Using models in vivo and in vitro we are analyzing the biology, genetics and molecular structure of these tumours, taking the study of stem cells as a starting point.

Clinical Research → The clinical trial called “Agnostos” is underway and its goal is to determine the molecular typing of the tumour with advanced methods to assess the possibility of identifying molecularly targeted therapies which allow us to offer patients new possibilities of care.

● SARCOMAS

Translational Research → Sarcomas are a heterogeneous group of diseases and this fact necessitates a specific diagnostic approach. Through studies conducted in our laboratories with analysis based on “new generation DNA sequencing”, we are seeking to identify those molecular alterations which lead to the development and growth of these tumours.

Clinical Research → Clinical trials are in progress which make use of new molecules active in the repair of tumoral DNA and programmed cell death and which act in synergy with other chemotherapeutic agents.

SWITCHBOARD

Telephone: +39 011.993.3111

PRESIDENT

Andrea Agnelli

GENERAL MANAGEMENT

Dr. A. Sottile

Telephone: +39 011.993.3685 - **Fax** +39 011.993.3546

E-mail: segreteria.direzionegenerale.fpo@ircc.it

SCIENTIFIC MANAGEMENT

Prof. A. Sapino

Telephone: +39 011.993.3887 - **Fax** +39 011.993.3118

E-mail: direzione.scientifica@ircc.it

HEALTHCARE MANAGEMENT

Dr. P. Fenu

Telephone: +39 011.993.3618 - **Fax** +39 011.993.3408

E-mail: dirsanircc@ircc.it

ADMINISTRATIVE MANAGEMENT

Dr. S. Nieddu

Telephone: +39 011.993.3685 - **Fax** +39 011.993.3546

E-mail: segreteria.direzioneamministrativa@ircc.it

PUBLIC RELATIONS OFFICE - U.R.P.

Telephone: +39 011.993.3618 - **Fax** +39 011.993.3408

E-mail: urp@ircc.it

CENTRE BOOKING OUT-PATIENT EXAMINATIONS - C.U.P.

Telephone: +39 011.993.3777

Operating Hours telephone bookings:
from Monday to Friday 9.00-12.30/ 13.30-15.30

Counter Opening Hours: 8.00-17.00

E-mail: segreteria.cup@ircc.it

RECEPTION CENTRE SERVICES

C.A.S. Dr. A. Capaldi

Telephone: +39 011.993.3806/079

Fax +39 011.993.3408

E-mail: segreteria.cas@ircc.it



ISTITUTO DI CANDIOLO - IRCCS

ISTITUTO DI CANDIOLO Fondazione del Piemonte per l'Oncologia
ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO

Strada Provinciale, 142 - KM 3.95 • 10060 Candiolo (TO) - ITALY

Switchboard: +39 011 993.3111 • www.fpoircc.it

HOW TO REACH THE INSTITUTE

By car

Tangenziale Sud (Turin South Bypass) Debouché exit. Strada Provinciale (Provincial Road) Stupinigi ring road, proceed towards Vinovo and then follow the signs for the IRCC.

By train

The 8 lines of the SFM (Metropolitan Railway Service) connect 93 stations all across Piedmont. On line SFM2, Candiolo can be reached directly from Turin Porta Susa railway station.

By bus

Service from and to Turin and Province. The bus stop is in front of the Institute on SS (State Road) 142. Autolinee Sadem - Via della Repubblica, 14 Grugliasco (TO)
Tel. +39 011.300.06.11 (from cellphone)
800.801.600 (from landline)
Bus Company (Turin and Cuneo)
Via Vigone, 8
Villafranca P.te - Tel. +39 011.980.00.00

By air

From Turin's Caselle airport, by the Metropolitan Railway Service (line SFMA) to Turin Porta Susa Station, then continue journey on line SFM2 to Candiolo station and thence by the MeBus service to the Institute. (further details on the website of Turin Airport).